Tamoxifen enhances therapeutic effects of gemcitabine on cholangiocarcinoma tumorigenesis
- 1 June 2011
- journal article
- research article
- Published by Elsevier in Laboratory Investigation
- Vol. 91 (6), 896-904
- https://doi.org/10.1038/labinvest.2011.60
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Synergistic Chemosensitivity of Triple-Negative Breast Cancer Cell Lines to Poly(ADP-Ribose) Polymerase Inhibition, Gemcitabine, and CisplatinCancer Research, 2010
- Cholangiocarcinoma: New Insights into Disease Pathogenesis and BiologyInfectious Disease Clinics of North America, 2010
- Fatal gemcitabine-induced pulmonary toxicity in metastatic gallbladder adenocarcinomaCancer Chemotherapy and Pharmacology, 2009
- Molecular Mechanisms of Tamoxifen Therapy for Cholangiocarcinoma: Role of CalmodulinClinical Cancer Research, 2009
- The enigma of caspase-2: the laymen's viewCell Death & Differentiation, 2008
- Chk1 Suppresses a Caspase-2 Apoptotic Response to DNA Damage that Bypasses p53, Bcl-2, and Caspase-3Cell, 2008
- Loss of Caspase-9 Reveals Its Essential Role for Caspase-2 Activation and Mitochondrial Membrane DepolarizationMolecular Biology of the Cell, 2007
- Combining Gemcitabine and Capecitabine in Patients With Advanced Biliary Cancer: A Phase II TrialJournal of Clinical Oncology, 2005
- Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR studyAnnals of Oncology, 2004
- A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474British Journal of Cancer, 1971